Early diagnosis, prognosis prediction, drug response assessment, and immunotherapy are crucial strategies for reducing mortality.[73,74] As early as 2009, Keenan J et al[75] found that CCT3 is associated with azithromycin resistance in lung squamous cell carcinoma (DLKP cell line). Here, CCT3 is linked to squamous cell lung carcinoma.